<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986138</url>
  </required_header>
  <id_info>
    <org_study_id>GDX-44-011</org_study_id>
    <nct_id>NCT03986138</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)</brief_title>
  <acronym>PROMISE</acronym>
  <official_title>Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guerbet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guerbet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial aims at evaluating the efficacy and the safety of gadopiclenol for body Magnetic
      resonance Imaging (MRI)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this trial is to evaluate a new gadolinium-based contrast agent (GBCA)
      gadopiclenol in terms of lesion visualization in patients referred for contrast-enhanced MRI
      of body regions.

      This is a prospective, international, multi-center, randomized, double-blind, controlled and
      cross-over trial.

      This trial will be conducted in approximately 50 centers worldwide. During the course of the
      trial, two MRIs will be obtained from each patient: one with gadopiclenol and one with
      gadobutrol. MRI evaluations will be assessed by independent off-site blinded readers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion visualization criteria for gadopiclenol-enhanced MRI compared to unhenhanced MRI</measure>
    <time_frame>1 day procedure</time_frame>
    <description>The lesion visualization criteria is based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed by independent blinded readers on the images acquired during the MRI performed with gadopiclenol for up to 3 most representative lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lesion visualization criteria for gadopiclenol-enhanced MRI compared to gadobutrol-enhanced MRI</measure>
    <time_frame>1 day procedure</time_frame>
    <description>The lesion visualization criteria is based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed by independent blinded readers on the images acquired during the MRI performed with gadopiclenol and MRI performed with gadobutrol for up to 3 most representative lesions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Lesion in Body Region</condition>
  <arm_group>
    <arm_group_label>gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadopiclenol</intervention_name>
    <description>Single intravenous bolus injection</description>
    <arm_group_label>gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI</arm_group_label>
    <arm_group_label>gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol 1 MMOLE/ML Intravenous Solution</intervention_name>
    <description>Single intravenous bolus injection</description>
    <arm_group_label>gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI</arm_group_label>
    <arm_group_label>gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient presenting with known or suspected enhancing abnormality(ies) and/or lesion(s)
             in at least one body region based on a previous imaging procedure performed within 12
             months prior to ICF signature. US patients are restricted to the breast in compliance
             with local approved indications of gadobutrol.

        Exclusion Criteria:

          -  Patient presenting with acute or chronic renal insufficiency, defined as an estimated
             Glomerular Filtration Rate (eGFR) &lt; 30 mL/min/1.73 mÂ² assessed within 1 day prior to
             each contrast agent administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corinne Dubourdieu, PharmD</last_name>
    <phone>+33145915000</phone>
    <email>corinne.dubourdieu@guerbet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

